$CSTL
CASTLE BIOSCIENCES INC

2022 Q3 Form 10-Q Financial Statement

#000144736222000137 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $37.01M $34.84M $26.85M
YoY Change 57.66% 53.08% 17.7%
Cost Of Revenue $8.859M $7.686M $5.944M
YoY Change 96.87% 107.9% 96.3%
Gross Profit $28.15M $27.15M $20.91M
YoY Change 48.36% 42.45% 5.68%
Gross Profit Margin 76.06% 77.94% 77.86%
Selling, General & Admin $36.63M $37.50M $30.45M
YoY Change 62.1% 80.09% 67.68%
% of Gross Profit 130.1% 138.1% 145.65%
Research & Development $10.91M $11.93M $10.76M
YoY Change 45.43% 75.56% 82.14%
% of Gross Profit 38.74% 43.92% 51.47%
Depreciation & Amortization $617.0K $531.0K $2.151M
YoY Change 56.2% 40.48% 823.18%
% of Gross Profit 2.19% 1.96% 10.29%
Operating Expenses $47.53M $49.42M $41.21M
YoY Change 57.94% 78.98% 71.23%
Operating Profit -$21.54M -$3.971M -$24.52M
YoY Change 82.29% -54.93% 472.27%
Interest Expense $6.000K $4.000K $3.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.25M -$3.605M -$24.49M
YoY Change 71.73% -58.97% 472.17%
Income Tax $0.00 -$1.957M $134.0K
% Of Pretax Income
Net Earnings -$20.25M -$1.648M -$24.62M
YoY Change 71.73% -81.25% 475.3%
Net Earnings / Revenue -54.71% -4.73% -91.7%
Basic Earnings Per Share -$0.77 -$0.06 -$0.97
Diluted Earnings Per Share -$0.77 -$0.06 -$0.97
COMMON SHARES
Basic Shares Outstanding 26.30M shares 26.06M shares 25.42M shares
Diluted Shares Outstanding 26.32M shares 26.06M shares 25.42M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $266.0M $273.2M $309.0M
YoY Change -26.76% -25.84% -24.07%
Cash & Equivalents $134.2M $273.2M $309.0M
Short-Term Investments $131.8M
Other Short-Term Assets $6.795M $5.775M $5.164M
YoY Change 23.55% 68.91% 66.58%
Inventory $3.802M $3.365M $2.350M
Prepaid Expenses
Receivables $22.84M $22.61M $19.91M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $299.4M $304.9M $336.4M
YoY Change -23.15% -22.16% -21.15%
LONG-TERM ASSETS
Property, Plant & Equipment $13.05M $11.20M $9.385M
YoY Change 47.24% 38.45% 20.63%
Goodwill $10.49M $10.49M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.195M $1.223M $2.699M
YoY Change -30.84% -25.02% 53.27%
Total Long-Term Assets $158.4M $153.5M $108.0M
YoY Change 259.11% 250.11% 912.79%
TOTAL ASSETS
Total Short-Term Assets $299.4M $304.9M $336.4M
Total Long-Term Assets $158.4M $153.5M $108.0M
Total Assets $457.8M $458.4M $444.4M
YoY Change 5.56% 5.25% 1.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.768M $3.281M $3.314M
YoY Change 108.53% 139.84% 52.58%
Accrued Expenses $24.45M $21.76M $13.19M
YoY Change 65.34% 96.05% 83.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.94M $27.52M $39.52M
YoY Change 52.16% 47.52% 124.83%
LONG-TERM LIABILITIES
Long-Term Debt $124.0K $158.0K $100.0K
YoY Change -87.42% -83.59%
Other Long-Term Liabilities $124.0K $158.0K $100.0K
YoY Change -91.67%
Total Long-Term Liabilities $124.0K $158.0K $100.0K
YoY Change -87.42% -83.59% -91.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.94M $27.52M $39.52M
Total Long-Term Liabilities $124.0K $158.0K $100.0K
Total Liabilities $46.38M $36.72M $47.09M
YoY Change 111.01% 87.18% 151.21%
SHAREHOLDERS EQUITY
Retained Earnings -$140.3M -$120.0M -$118.4M
YoY Change 60.59% 58.85% 77.29%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $411.4M $421.7M $397.3M
YoY Change
Total Liabilities & Shareholders Equity $457.8M $458.4M $444.4M
YoY Change 5.56% 5.25% 1.62%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$20.25M -$1.648M -$24.62M
YoY Change 71.73% -81.25% 475.3%
Depreciation, Depletion And Amortization $617.0K $531.0K $2.151M
YoY Change 56.2% 40.48% 823.18%
Cash From Operating Activities -$5.224M -$9.001M -$21.43M
YoY Change -14.82% 39.79% 490.2%
INVESTING ACTIVITIES
Capital Expenditures -$2.038M -$1.405M $402.0K
YoY Change 119.85% 53.89% -46.4%
Acquisitions
YoY Change
Other Investing Activities -$132.1M -$26.11M
YoY Change -3302900.0% -21.32%
Cash From Investing Activities -$134.1M -$27.51M -$402.0K
YoY Change 14434.13% -19.31% -46.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 388.0K 661.0K $1.216M
YoY Change -79.51% -65.04% -19.47%
NET CHANGE
Cash From Operating Activities -5.224M -9.001M -$21.43M
Cash From Investing Activities -134.1M -27.51M -$402.0K
Cash From Financing Activities 388.0K 661.0K $1.216M
Net Change In Cash -139.0M -35.85M -$20.62M
YoY Change 2592.48% -7.23% 618.08%
FREE CASH FLOW
Cash From Operating Activities -$5.224M -$9.001M -$21.43M
Capital Expenditures -$2.038M -$1.405M $402.0K
Free Cash Flow -$3.186M -$7.596M -$21.83M
YoY Change -38.8% 37.46% 398.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001447362
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
dei Document Type
DocumentType
10-Q
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38984
dei Entity Registrant Name
EntityRegistrantName
CASTLE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0701774
dei Entity Address Address Line1
EntityAddressAddressLine1
505 S. Friendswood Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 401
dei Entity Address City Or Town
EntityAddressCityOrTown
Friendswood
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77546
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
788-9007
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CSTL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26296968 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
273166000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329633000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22606000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17282000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
3365000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
2021000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5775000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4807000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
304912000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
353743000 usd
CY2022Q2 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1367000 usd
CY2021Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1308000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11203000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9501000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7004000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7383000 usd
CY2022Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
132671000 usd
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
88922000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1223000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1715000 usd
CY2022Q2 us-gaap Assets
Assets
458380000 usd
CY2021Q4 us-gaap Assets
Assets
462572000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3281000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2546000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14850000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15483000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1211000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1179000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8177000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5678000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
27519000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24886000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1949000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
18287000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6480000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6900000 usd
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
614000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
635000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
158000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
124000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
36720000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
50832000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Cost Of Revenue
CostOfRevenue
6725000 usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26292299 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26292299 shares
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
7686000 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
3697000 usd
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25378520 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25378520 shares
CY2022Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
26000 usd
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
25000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
541672000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
505482000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120038000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93767000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
421660000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
411740000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
458380000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462572000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34838000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22758000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61690000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45571000 usd
us-gaap Cost Of Revenue
CostOfRevenue
13630000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11926000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6793000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22687000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12701000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37498000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20822000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67951000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38983000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2097000 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
256000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3745000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
256000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-20398000 usd
CY2021Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-17836000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2022Q2 cstl Operating Expenses Net Of Other Operating Income
OperatingExpensesNetOfOtherOperatingIncome
38809000 usd
CY2021Q2 cstl Operating Expenses Net Of Other Operating Income
OperatingExpensesNetOfOtherOperatingIncome
31568000 usd
cstl Operating Expenses Net Of Other Operating Income
OperatingExpensesNetOfOtherOperatingIncome
90177000 usd
cstl Operating Expenses Net Of Other Operating Income
OperatingExpensesNetOfOtherOperatingIncome
58665000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3971000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8810000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-28487000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13094000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
370000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
400000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
28000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
4000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
7000 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-3605000 usd
CY2021Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-8786000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-28094000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-13066000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1957000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1823000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1648000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1648000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8791000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8791000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26271000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26271000 usd
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13071000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13071000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26064000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26064000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25091000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25091000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25746000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25746000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25002000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25002000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
415691000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4913000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
991000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1233000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4280000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418608000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4766000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1354000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8791000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
415937000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
411740000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8419000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
399000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-56000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1457000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24623000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
397336000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8783000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
110000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-32000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
17111000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1648000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
421660000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26271000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13071000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4779000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
867000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17202000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9679000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-17836000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1839000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-39000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-69000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5628000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5275000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
707000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1347000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1066000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-223000 usd
cstl Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-437000 usd
cstl Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-462000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-504000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
95000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
302000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-683000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-445000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-590000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1013000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-523000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2173000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1111000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-306000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30431000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10069000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1807000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1663000 usd
cstl Proceeds From Previous Asset Acquisition
ProceedsFromPreviousAssetAcquisition
547000 usd
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
33184000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
26661000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27913000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34845000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
336000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
509000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2345000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
88000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1511000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1392000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
55000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1877000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3401000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56467000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41513000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
329633000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
409852000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
273166000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
368339000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
696000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000 usd
us-gaap Stock Issued1
StockIssued1
17111000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
cstl Business Combination Noncash Contingent Consideration Given
BusinessCombinationNoncashContingentConsiderationGiven
1528000 usd
cstl Business Combination Noncash Contingent Consideration Given
BusinessCombinationNoncashContingentConsiderationGiven
0 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
313000 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
us-gaap Use Of Estimates
UseOfEstimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2021Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
9835000 usd
CY2021Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
12071000 usd
cstl Contract With Customer Customer Payment Terms
ContractWithCustomerCustomerPaymentTerms
P30D
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
578000 usd
CY2021Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-166000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-300000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5092000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34838000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22758000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61690000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45571000 usd
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5085000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3430000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4929000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3483000 shares
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
17883000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
12543000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
6680000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3042000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
11203000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
9501000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
531000 usd
CY2021Q2 us-gaap Depreciation
Depreciation
378000 usd
us-gaap Depreciation
Depreciation
1034000 usd
us-gaap Depreciation
Depreciation
611000 usd
CY2022Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2021Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2021Q4 us-gaap Goodwill
Goodwill
0 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
10494000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
10494000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
127881000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5704000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
122177000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
90880000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1958000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
88922000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
4611000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9147000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
9172000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9147000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9137000 usd
CY2022Q2 cstl Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
80963000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
122177000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3163000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1905000 usd
CY2022Q2 cstl Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2165000 usd
CY2021Q4 cstl Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
1655000 usd
CY2022Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
848000 usd
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
695000 usd
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
815000 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
760000 usd
CY2022Q2 cstl Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
469000 usd
CY2021Q4 cstl Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
10000 usd
CY2022Q2 cstl Business Combination Consideration Payable Current
BusinessCombinationConsiderationPayableCurrent
313000 usd
CY2021Q4 cstl Business Combination Consideration Payable Current
BusinessCombinationConsiderationPayableCurrent
0 usd
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
215000 usd
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
141000 usd
CY2022Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
189000 usd
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
512000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8177000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5678000 usd
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd
CY2021Q2 us-gaap Other Liabilities
OtherLiabilities
128000 usd
CY2022Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P10Y3M18D
CY2022Q2 cstl Lessee Operating Lease Lease Not Yet Commenced Amount
LesseeOperatingLeaseLeaseNotYetCommencedAmount
1400000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
18287000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
1528000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-17836000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1979000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3586688 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
231376 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
98953 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
140468 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
35.43
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3578643 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12314000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1599766 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
26.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10253000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8783000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4766000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17202000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9679000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
99493000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y

Files In Submission

Name View Source Status
0001447362-22-000137-index-headers.html Edgar Link pending
0001447362-22-000137-index.html Edgar Link pending
0001447362-22-000137.txt Edgar Link pending
0001447362-22-000137-xbrl.zip Edgar Link pending
cstl-20220630.htm Edgar Link pending
cstl-20220630.xsd Edgar Link pending
exhibit311-q22022.htm Edgar Link pending
exhibit312-q22022.htm Edgar Link pending
exhibit321-q22022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
cstl-20220630_cal.xml Edgar Link unprocessable
cstl-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cstl-20220630_lab.xml Edgar Link unprocessable
cstl-20220630_pre.xml Edgar Link unprocessable
cstl-20220630_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending